Literatur
- 1
Cauchi S, Meyre D et al.
Transcription factor TCF7L2 genetic study in the French population: expression in
human beta-cells and adipose tissue and strong association with type 2 diabetes.
Diabetes.
2006;
55
2903-2908
- 2
Dinarello C A, Donath M Y et al.
Role of IL-1beta in type 2 diabetes.
Curr Opin Endocrinol Diabetes Obes.
2010;
17
314-321
- 3
Florez J C.
The new typ 2 diabetes gene TCF7L2.
Curr Opin Clin Nutr Metab Care.
2007;
10
391-396
- 4
Larsen C M, Faulenbach M et al.
Interleukin-1-receptor antagonist in type 2 diabetes mellitus.
N Engl J Med.
2007;
356
1517-1526
- 5
Le Bacquer O, Shu L et al.
TCF7L2 splice variants have distinct effects on {beta}-cell turnover and function.
Hum Mol Genet.
2011;
20
1906-1915
- 6
Li D, Zhu S W et al.
Expression of interferon inducible protein-10 in pancreas of mice.
World J Gastroenterol.
2005;
11
4750-4752
- 7
Maedler K, Dharmadhikari G et al.
Interleukin-1 beta targeted therapy for type 2 diabetes.
Expert Opin Biol Ther.
2009;
9
1177-1188
- 8
Maedler K, Dharmadhikari G et al.
Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes.
Handb Exp Pharmacol.
2011;
203
257-278
- 9
Maedler K, Schumann D M et al.
Low Concentration of Interleukin-1{beta} Induces FLICE-Inhibitory Protein-Mediated
{beta}-Cell Proliferation in Human Pancreatic Islets.
Diabetes.
2006;
55
2713-2722
- 10
Maedler K, Sergeev P et al.
Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta
in human islets.
Proc Natl Acad Sci U S A.
2004;
101
8138-8143
- 11
Maedler K, Sergeev P et al.
Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity
in human pancreatic islets.
J Clin Invest.
2002;
110
851-860
- 12
Meier J J, Lin J C et al.
Direct evidence of attempted beta cell regeneration in an 89-year-old patient with
recent-onset type 1 diabetes.
Diabetologia.
2006;
49
1838-1844
- 13
Morimoto J, Yoneyama H et al.
CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese
diabetic mice through enhanced beta cell proliferation without affecting insulitis.
J Immunol.
2004;
173
7017-7024
- 14
Owyang A M, Maedler K et al.
XOMA 052, an Anti-IL-1{beta} Monoclonal Antibody, Improves Glucose Control and {beta}-Cell
Function in the Diet-Induced Obesity Mouse Model.
Endocrinology.
2010;
- 15
Prentki M, Nolan C J.
Islet beta cell failure in type 2 diabetes.
J Clin Invest.
2006;
116
1802-1812
- 16
Sauter N S, Schulthess F T et al.
The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat
diet-induced hyperglycemia.
Endocrinology.
2008;
149
2208-2218
- 17
Schulthess F T, Paroni F et al.
CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling.
Cell Metab.
2009;
9
125-139
- 18
Shu L, Matveyenko A V et al.
Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation
of GIP- and GLP-1 receptors and impaired beta-cell function.
Hum Mol Genet.
2009;
18
2388-2399
- 19
Shu L, Sauter N S et al.
Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic
islets.
Diabetes.
2008;
57
645-653
- 20
Sladek R, Rocheleau G et al.
A genome-wide association study identifies novel risk loci for type 2 diabetes.
Nature.
2007;
445
881-885
Prof. Dr. K. Maedler
Universität Bremen · FB 2 Biologie / Chemie · Biomolekulare Interaktionen
Leobener Str. im NW2
28359 Bremen
Phone: 04 21 / 21 86 32 90
Fax: 04 21 / 2 18 42 79
Email: kmaedler@uni-bremen.de
